RefleXion Medical adds Frederic H. Moll to its Board of Directors

January 19, 2016

Pioneer in Surgical Robotics and Minimally Invasive Surgery to Contribute in Moving Revolutionary Biologically-Guided Radiotherapy System Into the Clinic

HAYWARD, CA–(Marketwired – January 19, 2016) – RefleXion Medical, a medical equipment company developing the first biologically-guided radiation therapy system for cancer treatment, announced today that it has appointed Frederic H. Moll, M.D. to the company’s Board of Directors.

“Dr. Moll has an unrivaled track record of clinical innovation and bringing disruptive, minimally-invasive surgical technologies to patients,” said Dr. Samuel Mazin, President of RefleXion and inventor of the company’s core technology. “Given RefleXion’s potential to enable whole body multi-site radiosurgery for advanced stage cancer patients with very limited treatment options, we are incredibly excited to add Fred’s wealth of experience and judgement to RefleXion.”

Dr. Moll currently serves as Chairman and Chief Executive Officer of Auris Surgical Robotics, Inc., the fourth surgical robotics company he has founded. In 1995, Dr. Moll co-founded Intuitive Surgical, Inc. (ISRG), the world leader in surgical robotics. He served as Intuitive’s CEO through 1996 and a Director through 2004.

Prior to Intuitive Surgical, Dr. Moll co-founded OriginMedsystems, Inc., which became an operating company within Guidant Corporation following the acquisition by Eli Lilly in 1992. Dr. Moll served as medical director of Guidant’s surgical device division from 1992-1995. Before co-founding Origin Medsystems, Dr. Moll invented the safety trocar, which fostered in modern general laparoscopic surgery and founded Endotherapeutics, which was acquired by U.S. Surgical in 1992. Dr. Moll was also founding CEO of the intravascular robotics company, Hansen Medical, Inc. and was a Director of the leading hard-tissue orthopedics robotics company, MAKO Surgical (acquired by Stryker).

“I am very excited to be joining the RefleXion Board because their biologically-guided radiotherapy technology could transform oncology care not only for early-stage cancer patients but for patients where surgery and radiosurgery are not currently viable options,” said Dr. Moll.